We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Why Is Penumbra (PEN) Up 5% Since Last Earnings Report?
Read MoreHide Full Article
A month has gone by since the last earnings report for Penumbra (PEN - Free Report) . Shares have added about 5% in that time frame, outperforming the S&P 500.
But investors have to be wondering, will the recent positive trend continue leading up to its next earnings release, or is Penumbra due for a pullback? Before we dive into how investors and analysts have reacted as of late, let's take a quick look at the most recent earnings report in order to get a better handle on the important catalysts.
Penumbra Q2 Earnings , Revenues Beat Estimates
Penumbra reported second-quarter 2025 adjusted earnings per share of 86 cents, which surpassed the Zacks Consensus Estimate by 6.2%. Year-ago adjusted EPS remained at a breakeven level.
GAAP earnings were $1.15 per share compared with a loss of $1.55 per share in the prior-year period.
PEN Q2 Revenues
Penumbra registered revenues of $339.5 million in the reported quarter, up 13.4% year over year on a reported basis and 12.7% constant exchange rate or CER. The figure topped the Zacks Consensus Estimate by 3.5%.
Penumbra’s 2025 Outlook
The company updated its 2025 revenue guidance to the range of $1.355-1.370 billion from earlier band of $1.34-$1.36 billion. This represents 13%-15% growth over 2024 revenue of $1.195 billion.
Meanwhile, Penumbra maintains guidance for U.S. Thrombectomy growth range at 20%-21% year over year.
Penumbra continues to expect gross margin expansion of at least 100 bps to more than 67% and operating margin expansion to a range of 13%-14% of revenues for full-year 2025.
How Have Estimates Been Moving Since Then?
In the past month, investors have witnessed a downward trend in estimates revision.
The consensus estimate has shifted -5.52% due to these changes.
VGM Scores
At this time, Penumbra has a nice Growth Score of B, though it is lagging a lot on the Momentum Score front with an F. Charting a somewhat similar path, the stock has a score of D on the value side, putting it in the bottom 40% for value investors.
Overall, the stock has an aggregate VGM Score of D. If you aren't focused on one strategy, this score is the one you should be interested in.
Outlook
Estimates have been broadly trending downward for the stock, and the magnitude of these revisions indicates a downward shift. Notably, Penumbra has a Zacks Rank #3 (Hold). We expect an in-line return from the stock in the next few months.
Performance of an Industry Player
Penumbra belongs to the Zacks Medical - Instruments industry. Another stock from the same industry, AngioDynamics (ANGO - Free Report) , has gained 11.7% over the past month. More than a month has passed since the company reported results for the quarter ended May 2025.
AngioDynamics reported revenues of $80.16 million in the last reported quarter, representing a year-over-year change of +12.9%. EPS of -$0.03 for the same period compares with -$0.06 a year ago.
AngioDynamics is expected to post a loss of $0.13 per share for the current quarter, representing a year-over-year change of -18.2%. Over the last 30 days, the Zacks Consensus Estimate has changed -2.7%.
The overall direction and magnitude of estimate revisions translate into a Zacks Rank #3 (Hold) for AngioDynamics. Also, the stock has a VGM Score of B.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Why Is Penumbra (PEN) Up 5% Since Last Earnings Report?
A month has gone by since the last earnings report for Penumbra (PEN - Free Report) . Shares have added about 5% in that time frame, outperforming the S&P 500.
But investors have to be wondering, will the recent positive trend continue leading up to its next earnings release, or is Penumbra due for a pullback? Before we dive into how investors and analysts have reacted as of late, let's take a quick look at the most recent earnings report in order to get a better handle on the important catalysts.
Penumbra Q2 Earnings , Revenues Beat Estimates
Penumbra reported second-quarter 2025 adjusted earnings per share of 86 cents, which surpassed the Zacks Consensus Estimate by 6.2%. Year-ago adjusted EPS remained at a breakeven level.
GAAP earnings were $1.15 per share compared with a loss of $1.55 per share in the prior-year period.
PEN Q2 Revenues
Penumbra registered revenues of $339.5 million in the reported quarter, up 13.4% year over year on a reported basis and 12.7% constant exchange rate or CER. The figure topped the Zacks Consensus Estimate by 3.5%.
Penumbra’s 2025 Outlook
The company updated its 2025 revenue guidance to the range of $1.355-1.370 billion from earlier band of $1.34-$1.36 billion. This represents 13%-15% growth over 2024 revenue of $1.195 billion.
Meanwhile, Penumbra maintains guidance for U.S. Thrombectomy growth range at 20%-21% year over year.
Penumbra continues to expect gross margin expansion of at least 100 bps to more than 67% and operating margin expansion to a range of 13%-14% of revenues for full-year 2025.
How Have Estimates Been Moving Since Then?
In the past month, investors have witnessed a downward trend in estimates revision.
The consensus estimate has shifted -5.52% due to these changes.
VGM Scores
At this time, Penumbra has a nice Growth Score of B, though it is lagging a lot on the Momentum Score front with an F. Charting a somewhat similar path, the stock has a score of D on the value side, putting it in the bottom 40% for value investors.
Overall, the stock has an aggregate VGM Score of D. If you aren't focused on one strategy, this score is the one you should be interested in.
Outlook
Estimates have been broadly trending downward for the stock, and the magnitude of these revisions indicates a downward shift. Notably, Penumbra has a Zacks Rank #3 (Hold). We expect an in-line return from the stock in the next few months.
Performance of an Industry Player
Penumbra belongs to the Zacks Medical - Instruments industry. Another stock from the same industry, AngioDynamics (ANGO - Free Report) , has gained 11.7% over the past month. More than a month has passed since the company reported results for the quarter ended May 2025.
AngioDynamics reported revenues of $80.16 million in the last reported quarter, representing a year-over-year change of +12.9%. EPS of -$0.03 for the same period compares with -$0.06 a year ago.
AngioDynamics is expected to post a loss of $0.13 per share for the current quarter, representing a year-over-year change of -18.2%. Over the last 30 days, the Zacks Consensus Estimate has changed -2.7%.
The overall direction and magnitude of estimate revisions translate into a Zacks Rank #3 (Hold) for AngioDynamics. Also, the stock has a VGM Score of B.